

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/000035 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61P 35/00 (2006.01)
A61K 9/08 (2006.01)

(21) International Application Number:

PCT/AU2024/050685

(22) International Filing Date:

27 June 2024 (27.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023902019 27 June 2023 (27.06.2023) AU

(71) Applicant: **CLARITY PHARMACEUTICALS LIMITED** [AU/AU]; National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(72) Inventors: **HARRIS, Matthew John**; c/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **PARKER, Michelle**; c/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **LENGYELOVA, Eva**; c/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **HEDT, Amos**; c/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **BIGGIN, Colin**; c/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; Level 15, 1 Nicholson Street, Melbourne, Victoria 3000 (AU).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHODS FOR THE DIAGNOSIS AND/OR TREATMENT OF NEUROENDOCRINE CANCERS



Formula (I)

(57) Abstract: The present invention relates to methods of diagnosis and/or radiotherapy, comprising the administration of a compound of Formula (I) and a ^{64}Cu / ^{67}Cu radioisotope to deliver a targeted dose of radiation for the diagnosis and treatment of a neuroendocrine cancer, particularly neuroblastoma in children.



WO 2025/000035 A1